ArticleFrontiers in cellular and infection microbiology2026
Post-EV71 vaccination outcomes in meningoencephalitis: no increased clinical severity compared with other enterovirus subtypes in a single-center retrospective study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess clinical differences and prognosis between pediatric meningoencephalitis caused by EV71 and other enterovirus subtypes in the context of widespread EV71 vaccination, and to evaluate changes in the clinical profile of EV71 infection in the vaccine era. Methods: We enrolled 160 children with enterovirus-associated meningoencephalitis admitted to Kunming Children's Hospital between January 2019 and August 2024. Patients were categorized into an EV71 group and an EV-others group based on etiology. Demographic, clinical, laboratory, and outcome data were collected. Results: Of the 160 cases, 75 (46.0%) were EV-unclassified, 45 (27.6%) EV-A6, 20 (12.3%) EV71, 14 (8.6%) EV-A16, and 9 (5.5%) EV-A10. No significant between-group differences in sex, age, or weight were found. The EV71 group had a longer duration of fever (median 3.5 days vs 2 days, P = 0.032) and a higher frequency of hand-foot vesicular lesions (20/20, 100% vs 99/140, 71%, P = 0.011). Laboratory results showed higher platelet counts and lymphocyte counts in the EV71 group. In contrast, CRP, ferritin, ALT, and CD16 + 56+ levels were lower in the EV71 group. CSF analysis showed significantly higher cell counts (55.5 vs 12 ×10 Conclusion: In the era of widespread EV71 vaccination, pediatric meningoencephalitis caused by EV71 no longer presents worse overall outcomes than other enterovirus subtypes. EV71 remains associated with a stronger central but weaker systemic inflammatory response, suggesting a distinct inflammatory profile. Continued surveillance and multivalent vaccine development are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.